Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q3 EPS of $0.14, $0.02 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $70.1 million versus the consensus estimate of $75 million.

For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.